voretigene neparvovec-rzyl

Phase 2

TherapeuticsMD, Inc. (TXMD)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Leber Congenital Amaurosis

View Full Landscape

Drug Information

Target Indication

Leber Congenital Amaurosis

Clinical Trial

NCT01208389

Last updated: 7/25/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA11/22/2018

Luxturna

Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

TXMD

TherapeuticsMD, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

JDP-205 InjectionPhase 3

Acute Urticaria

LeriglitazonePhase 3

Cerebral Adrenoleukodystrophy (cALD)

Oxymorphone immediate releasePhase 3

Acute Pain

DifluprednatePhase 3

Inflammation

TiratricolPhase 3

Monocarboxylate Transporter 8 Deficiency

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts